Research Article

Therapy Effects of Wogonin on Ovarian Cancer Cells

Jiang Ruibin,1 Jin Bo,2 Wan Danying,1 Zhu Chihong,1 Feng Jianguo,1,3 and Gu Linhui1,3

1Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China
2College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China
3Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, Zhejiang 310022, China

Correspondence should be addressed to Gu Linhui; linhuigu@yeah.net

Received 24 June 2017; Revised 23 August 2017; Accepted 10 September 2017; Published 18 October 2017

Academic Editor: Gang Liu

Copyright © 2017 Jiang Ruibin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Wogonin is a plant monoflavonoid and has been reported to induce apoptosis of cancer cells and show inhibitory effect on cancer cell growth. However, the detailed and underlying molecular mechanisms are not elucidated. In this study, we investigated the molecular and biological effects of wogonin in human ovarian A2780 cancer cells.

Materials and Methods. We determined the effects of wogonin on the changes of cell cycling and apoptotic responses of cells. Western blot analysis was used to measure the effects of wogonin on protein expressions.

Results. Our results showed that treatment with wogonin inhibited the cancer cell proliferation, decreased the percentage of G0/G1 subpopulation, and reduced invasiveness of A2780 cells. Exposure to wogonin also resulted in downregulated protein levels of estrogen receptor alpha (ER-α), VEGF, Bcl-2, and Akt and increased expressions of Bax and p53. In addition, exposure to wogonin increased caspase-3 cleavage and induced apoptosis in A2780 cells. Our study further showed that MPP, a specific ER-α inhibitor, significantly enhanced antitumor effects of wogonin in A2780 cells.

Conclusion. Our results suggest a potential clinical impact of wogonin on management of ovarian cancer.

1. Introduction

Ovarian cancer is an estrogen-dependent disease and the leading cause of mortality in women, with more than 204,000 cases diagnosed in the world every year. Eighty-five percent of ovarian cancer is epithelial disease, and surgery is the first-line treatment. Other treatment options such as radiation therapy, hormonal therapy, and chemotherapy may also be applied based on tumor stages [1, 2].

Estrogen stimulation plays vital role in cancer development and progression, which is regulated by estrogen receptor (ER-α), for this disease [3–5]. ER-α mediates both genomic signaling pathways and nongenomic signaling pathways, regulating cancer cell proliferation [6, 7]. Studies [8–10] have also suggested a potential of ER-α overexpression or increase of ER-α/β expression ratio, on selective growth advantage for ER-α positive cells during the development and progression of ovarian cancer. Indeed, exposure to exogenous estrogen was found to promote the viability of ER-positive ovarian cancer cell lines [11, 12]. For example, Choi et al. [13] reported that overexpression of ER-α, but not ER-β, significantly promoted the growth of ovarian carcinoma A2780 and OVCAR-3 cells, and silencing of ER-α expression dramatically reduced cell growth of ovarian cancer BG-1 cells. Thus, targeting estrogen receptor (ER) signaling became a clinical management for ovarian cancer patient. To this setting, tamoxifen, as an agent of selective estrogen receptor modulator (SERM), has been used to treat ovarian stromal tumors. However, tamoxifen may cause severe adverse effects such as increased risk of serious blood clots due to its weak estrogen activity, and the resistance developed during tamoxifen treatment is another clinical challenge [14–16]. Therefore, there is urgent need to develop novel agents targeting and intervening in ER signaling for ovarian cancer treatment with lower toxic and minimized adverse effects to improve clinical outcomes for this disease.

Flavonoids are a class of plant secondary metabolites and polyphenolic compounds that can be taken from natural products [17]. Flavonoids were found to be able to act as antitumor and antioxidant agents [18, 19]. Of them, wogonin from traditional Chinese herb Scutellaria baicalensis Georgi has been widely used and researched for allergic and inflammatory diseases with its medication effects of potential “cleansing heat” and “removing toxins” [20, 21]. Previous
studies have shown inhibitory effects of wogonin on a number of different cancerous cells [22, 23]. The mechanisms of its anticancer activities include modulation of p53 signaling pathway [24, 25], inducing G1 phase arrest [26], antitumor angiogenesis by inhibition of VEGF [27, 28], and inhibition of apoptosis through the mitochondrial pathway [29]. In addition, a study also demonstrated the antiproliferative activities of wogonin in epithelial ovarian carcinoma (EOC) cells and six primary cultured EOC with disease stages III–IV, and the observed inhibitions on cell growth were reported through phytochemicals-induced cell-cycle modulation and apoptosis induction [1]. These studies indicate that wogonin is a new anticancer agent with enhancement of the curative effect on chemoinsensitive tumors that may clinically benefit ovarian cancer patients.

In this study, we present data showing the detailed mechanisms by which wogonin modulate the ER-α signaling pathway and inhibit cancer cell growth of ovarian carcinoma.

2. Materials and Methods

2.1. Reagents. A2780 cells were purchased from Sigma-Aldrich Co. (St Louis, MO) and were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS, Gibco). Cells were tested with a Cell Culture Contamination Detection Kit (Thermo Fisher Scientific) and results appeared negative for mycoplasma contamination. Wogonin, with a chemical structure shown in Figure 1(a), was purchased from Aokebio (Beijing, China). Methylpiperidinopyrazole (MPP) was purchased from Apexbio. The antibodies were from Abcam (Akt, β-actin), Proteintech (caspase-3, cleaved-caspase-3, cyclin D1, CDK4, and CDK6), Santa Cruz Biotechnology (ER-α), and Cell Signaling Technology (Bcl-2, Bax, VEGF, and p53).

2.2. Cell Viability Analysis. Cells were plated in 96-well plates (5 × 10^3 cells/well). 24 hours later, cells were exposed to increasing concentrations of wogonin and/or MPP, and DMSO was included as control. MTT assay was performed for measuring cell viability according to manufacturer’s instruction (Promega, USA).

2.3. Invasion Assay. After treatment with wogonin or MPP for 48 hours, 5 × 10^4 cells were seeded in cell culture inserts with 1% FBS. Culture medium with 10% FBS was placed outside the chambers. Cells that invaded the attractant of 10% FBS medium were visualized and counted after 48 h. The method was previously reported [30].

2.4. Clonogenic Assay. Cells were plated in 60 mm dishes (1000/dish) and were treated with different concentrations of wogonin or MPP for 48 hours. Cells were cultured for two additional weeks. Colonies (>50 cells) were stained with crystal violet prior to being counted under an inverted microscope [30].

2.5. Wound Scratch Assay. Cultured cells in confluent monolayer were wounded using a needle to scratch the surface. Cells were then exposed to wogonin for 48 h. Cell movement and initial wounding were imaged and analyzed by Image J software.

2.6. Apoptosis Assay. Log-phase growing cells were treated with wogonin for 48 hours. The cells were collected and washed with PBS and were then incubated with staining buffer containing Annexin V-FITC and PI according to manufacturer’s instruction (BD Pharmingen, number 556547); apoptotic cells (FITC+/PI−) were quantified by flow cytometry. For fluorescence microscopy analysis, cells were seeded in 96-well plates at 5 × 10^3/well and were then exposed to different doses of wogonin and MPP for 48 hours. After treatment, 5 μg/ml Hoechst 33342 and 10 μg/ml PI were added to the cultured cells. 40 minutes later, cells were collected, and fluorescence microscopy analysis was used for assessment of cell morphology.

2.7. Cell-Cycle Analysis. Cells were plated in 6-well plates at 2.0 × 10^5/well. 24 hours later, cells were treated with
different concentrations of wogonin for 48 hours. Cells were then collected and fixed with 70% ethanol (prepared by PBS) at −4°C. The fixed cells were incubated with RNase A (100 μg/mL) and PI (50 μg/mL) in PBS for 30 min. The cell cycling was determined using flow cytometry analysis with CXP software, and results were analyzed with Cytomtics™ FC 500 software (Beckman).

2.8. Western Blot Analysis. A2780 cells were collected and lysed with RIPA lysis buffer (Beyotime, China) containing 1 mM PMSF. 25 μg of cell lysate was loaded onto 10% SDS-polyacrylamide gels for immunoblot analysis. All primary antibodies were used at 1:500 to 1:1000 dilutions in this study, and beta-actin was included for equal protein loading [31].

2.9. Statistical Analysis. Statistical analyses were performed by Student’s t-test with one-way ANOVA (P < 0.05) [32].

3. Results

3.1. Antitumor Effects of Wogonin on A2780 Ovarian Cancer Cells. We first examined effects of wogonin on cell proliferation of A2780 cells. In this experiment, we used DMSO as control. Our results showed that wogonin dramatically inhibited cell proliferation of A2780 cells, and the inhibitory effect of wogonin on A2780 cells is dependent on the dose of wogonin (Figure 1(b)).

3.2. Wogonin Decreased Invasiveness and Migration of A2780 Cells. We next determined the effects of wogonin on invasiveness and migration of A2780 cells. With invasion assay and wound scratch assay, we found that treatment with wogonin dramatically decreased cancer cell capabilities of invasion and migration, and these inhibitory effects are also dose-dependent (Figures 2(a)–2(c)).

We further tested the potential enhancement of antitumor effects of wogonin in ovarian cancer cells where ER-α signaling was blocked by treatment of methylpyridinepyrazole (MPP), and our results showed that MPP significantly enhanced the inhibitory effects of wogonin on invasiveness and clonogenic survival of A2780 cells (Figures 2(c)–2(e)). Of interest, Western blot analysis (Figure 2(f)) showed that wogonin also downregulates ER-α expression. These results suggest that ER-α signaling pathway might interact with the inhibitory effects of wogonin on cancer cell invasiveness and migration of A2780 cells. In addition, our results further showed that exposure to wogonin increased p53 expression and decreased the protein level of VEGF (Figure 2(f)).

3.3. Wogonin Induces Apoptosis in A2780 Cells. To determine the potential apoptosis and death as the inhibitory effect of wogonin and MPP in A2780 cells, we performed Annexin V-FITC staining in cells with treatment of wogonin and MPP. Our results (Figure 3(a)) showed that treatment with wogonin or MPP increased both early and late apoptosis in A2780 cells. Of note, the combination of wogonin with MPP resulted in significant increase of the apoptosis-induction effect of wogonin in A2780 cells. Microscopy analyses with fluorescence staining of Hoechst 33342 and PI also demonstrated identical morphological changes of A2780 cells. We detected nuclear modifications of fragmentation and chromatin condensation in cells that were treated with wogonin, and our results suggested these changes are dependent on the dose of wogonin (Figure 3(b)).

The Bcl-2 and caspase cascade play essential roles in balancing antiapoptosis and proapoptosis of cells and integrate a wide range of diverse upstream survival and death signals to determine the fate of cells. In A2780 cells treated with wogonin or MPP, we detected decreased levels of Akt and Bcl-2 (Figure 3(c)). However, exposure to wogonin or MPP increased Bax protein level and caspase-3 cleavage. These results suggest that wogonin and MPP can regulate the expression of Bcl-2 family proteins and the activation of caspase cascade, resulting in increase of apoptosis in ovarian cancer cells.

3.4. Wogonin Causes Cell-Cycle Arrest in A2780 Ovarian Cancer Cells. Recent studies have shown that wogonin can also induce cell-cycle arrest through the regulation of the expression of cell-cycle regulators in various cancers. In this study, we determined the cell cycling change of A2780 cells when cells were treated with wogonin and MPP. Our results showed that both wogonin and MPP treatments (48 hours) led to dramatic decrease of the G0/G1 subpopulation of A2780 cells (Figures 4(a) and 4(b)). Western blot analysis (Figure 4(c)) further revealed that treatment with wogonin or MPP reduced expressions of G0/G1 phase-related proteins cyclin D1, CDK4, and CDK6. We also found that combined treatment with wogonin and MPP reduced G0/G1 phase and decreased the expressions of cyclin D1, CDK4, and CDK6.

4. Discussion

One of the major clinic challenges in treating cancer is to optimize the therapeutic strategy with maximizing therapy efficacy and minimizing adverse effects in patients [33]. To this setting, traditional Chinese medicines (TCM) have been considered as a resource for selection of novel anticancer drugs.

Previous studies have reported that plant flavonoids possess antitumor and anti-inflammatory effects. Studies also revealed that wogonin induces apoptosis through the modulation of apoptotic factors [34, 35] and induces change of cell cycling by regulation of the cyclin D1 expression in human breast cancer [36]. The histopathogenesis of ovarian cancer is very similar to that of breast cancer with the potential of estrogen and its receptors, such as ER-α, as carcinogens. However, the correlation of wogonin and ER-α expression has not been demonstrated in ovarian cancer. Our present data show that wogonin inhibits cancer cell proliferation and reduces clonogenic survival ability of ovarian cancer cells. Treatment with wogonin also decreases the percentage of G0/G1 subpopulation. Of interest, we observed downregulated expression of ER-α in A2780 cells when cells were exposed to wogonin, suggesting that the antitumor activity of wogonin may interact with ER-α signaling. In clinical practice, estrogen receptor is recognized as a prognostic
Figure 2: Combination effects of wogonin and MPP on cancer cell invasion and clonogenic survival in A2780 ovarian cancer cells. ((a) and (b)) Wogonin inhibits A2780 ovarian cancer cells migration. Representative images of wound scratch assay showing the effect of wogonin on cell migration. Graph showing the change of inhibition ratio for wound scratch healing. (c) Invasion assay. Representative images showing the effect of wogonin on cancer cell invasiveness. (d) Combined effects of wogonin and MPP on clonogenic survival of A2780 ovarian cancer cells. Representative images showing the surviving colonies. (e) Graphs showing the changes of clonogenic survival fraction. The error bars represent the standard error, *P < 0.05 versus control group and **P < 0.05 versus wogonin + MPP group, n = 3. (f) Western blot analysis showing the effects of wogonin and MPP on ER-α, VEGF, and p53 protein expression in A2780 ovarian cancer cells. β-Actin was included as a loading control. Data present average results from three independent experiments; SD means the standard deviation (n = 3).
Figure 3: Wogonin treatment induces apoptosis in A2780 ovarian cancer cells. (a) Representative images showing apoptosis detected with Annexin V-FITC and PI staining in A2780 cells. Percentage of the bottom right quadrant and the top right quadrant showing the representative events of early and late apoptosis, respectively. (b) Representative images of fluorescence microscopy analysis showing the effects of treatment with wogonin, MPP, and the combination on nuclei apoptosis and cell necrosis in A2780 cells. Cells were stained with Hoechst and PI, and images were taken under magnification of ×200. (c) The protein expression of Akt, Bcl-2, Bax, cytochrome C, caspase-3, and cleaved-caspase-3. β-Actin was included as a loading control.

factor for breast cancer and a critical reference for clinical management of breast cancer. Although no prognostic value for ER expression has been suggested for ovarian cancers, up to 60% of ovarian epithelial tumors were reported to have ER overexpression, suggesting a potential of regulatory effects of estrogen signaling for deployment and progression of ovarian cancer, and thus targeting ER-α signaling may benefit ovarian cancer patients. To this setting, our results suggest wogonin may act on estrogen signaling as a novel therapeutic agent for ovarian tumor treatment.

Several cancer-related proteins, such as p53 and VEGF, play vital roles in cancer development and progression. These proteins are valuable therapeutic targets for cancer treatment [37, 38]. In this study, our results showed that treatments with wogonin, or wogonin combined with MPP, resulted in dramatic increase of p53 protein expression and decrease of VEGF protein expression in A2780 cells. In addition, much effort in screening of TCM as novel therapeutic agents for cancer treatment has been devoted to testing the capability of TCM for apoptosis induction in cancer cells and in xenograft tumors. Apoptosis is a vital phenomenon that controls cancer cell growth and survival. When cancer cells enter apoptosis, mitochondrial cell death and death receptor pathways are two major pathways that are involved in cancer cell programmed death. In mitochondrial cell death signaling, the accumulation of Bcl-2 family proteins and the ratio of Bax/Bcl-2 in mitochondrial membrane determine the potential release of cytochrome C from the intermembrane space of mitochondria to cytoplasm, where it promotes the formation of the apoptosome and activates the caspase cascade that leads to cell apoptosis [39, 40]. However, ER-α signaling can protect cells from apoptosis [41]. Of interest, we revealed in this study that wogonin not only modulates expression of Bcl-2 family protein, allowing cell entering apoptosis, but also modulates...
ER-α expression to reduce protection activity of estrogen on apoptosis in ovarian cancer cells. On the other hand, ER-α activation regulates expressions of cell-cycle-related proteins, such as cyclin D1 [42]. Cyclin D1 is a regulatory subunit of cyclin-dependent kinases CDK4 and CDK6 and is a key element controlling transition of cells from G1 phase and S phase [43–45]. Of interest, our results also showed that wogonin alone or combined with MPP reduced the protein levels of cyclin D1, CDK4, and CDK6. Taken together, these results also suggest that wogonin can act as an epigenetic therapy agent for ovarian cancer.

In conclusion, the present data suggests a potential clinical impact of wogonin for ovarian cancer patients. However, further investigation of wogonin as an anticancer drug candidate is needed.

**Conflicts of Interest**

The authors have no conflicts of interest to declare.

**Acknowledgments**

This work was supported by the Natural Science Foundation of Zhejiang Province (LQ12H16015, LY13H160028), Zhejiang Provincial Medicine and Health Science Fund (2015KYA035, 2017KY238), and National Scientific Foundation of China (81302840).

**References**

[1] S. Chen, M. Cooper, M. Jones et al., “Combined activity of oridonin and wogonin in advanced-stage ovarian cancer cells,” *Cell Biology and Toxicology*, vol. 27, no. 2, pp. 133–147, 2011.

[2] J. Spiliotis, E. Halkia, E. Lianos et al., “Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study,” *Annals of Surgical Oncology*, vol. 22, no. 5, pp. 1570–1575, 2015.

[3] A. L. Shafrir, M. S. Rice, M. Gupta et al., “The association between reproductive and hormonal factors and ovarian cancer by estrogen-α and progesterone receptor status,” *Gynecologic Oncology*, vol. 143, no. 3, pp. 628–635, 2016.

[4] E. Dudko, T. Bogush, S. Kolomiytsev et al., “Quantitative analysis of estrogen receptors alpha and beta expression in ovarian cancer patients by flow cytometry,” *European Journal of Cancer*, vol. 61, p. S71, 2016.

[5] M. van Kruchten, E. F. J. de Vries, H. J. G. Arts et al., “Assessment of estrogen receptor expression in epithelial ovarian cancer
patients using 16α-18\(^{-}\)F-fluoro-17\(^{\beta}\)-estradiol PET/CT,” *Journal of Nuclear Medicine*, vol. 56, no. 1, pp. 50–55, 2015.

[6] M.-A. Park, K.-A. Hwang, H.-R. Lee, B.-R. Yi, E.-B. Jeung, and K.-C. Choi, “Benzophenone-1 stimulated the growth of BG-1 ovarian cancer cells by cell cycle regulation via an estrogen receptor alpha-mediated signaling pathway in cellular and xenograft mouse models,” *Toxicology*, vol. 305, pp. 41–48, 2013.

[7] J. Lu, Y. Xu, X. Wei, Z. Zhao, J. Xue, and P. Liu, “Emodinin inhibits the epithelial to mesenchymal transition of epithelial ovarian cancer cells via ILK/GSK-3β/Slug signaling pathway,” *BioMed Research International*, vol. 2016, Article ID 6253280, 16 pages, 2016.

[8] K.-L. Chan, T. H.-Y. Leung, D. W. Chan et al., “Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer,” *Journal of Endocrinology*, vol. 221, no. 2, pp. 325–336, 2014.

[9] J. Fujimoto, R. Hirose, H. Sakaguchi, and T. Tamaya, “Clinical significance of expression of estrogen receptor α and β mRNAs in ovarian cancers,” *Oncology*, vol. 58, no. 4, pp. 334–341, 2000.

[10] J. Lu, Q. Zhuang, X. Lan, G. Zeng, X. Jiang, and Z. Huang, “PESI differentially regulates the expression of ERα and ERβ in ovarian cancer,” *IUBMB Life*, vol. 65, no. 12, pp. 1075–1025, 2013.

[11] C.-H. Chien, F.-F. Wang, and T. C. Hamilton, “Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells,” *Molecular and Cellular Endocrinology*, vol. 99, no. 1, pp. 11–19, 1994.

[12] M. Galtier, J. M. Nores, and J. M. Remy, “Beta blockade prophylaxis of accessory pathway catecholamine sensitive circus movement tachycardia,” *The European journal of medicine*, vol. 1, no. 2, pp. 125–126, 1992.

[13] J.-H. Choi, K.-T. Lee, and P. C. K. Leung, “Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth,” *Carcinogenesis*, vol. 32, no. 4, pp. 589–596, 2011.

[14] A. Scafonas, A. A. Reszka, D. B. Kimmel et al., “Agonist-like effects of ERα-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 110, no. 3-5, pp. 197–206, 2008.

[15] Sharma SFCMWTSYA, “Determining the role of somatic ERα mutations in acquired hormone (or SERM) resistance,” *Cancer Research*, vol. 75, no. 9, article 4, 2015.

[16] K. Ohta, T. Ogawa, A. Kaise, and Y. Endo, “Synthesis and biological evaluation of novel m-carborane-containing estrogen receptor partial agonists as SERM candidates,” *Bioorganic and Medicinal Chemistry Letters*, vol. 25, no. 16, pp. 3213–3216, 2015.

[17] J. L. Dower, J. M. Geleijnse, L. Gijsbers, P. L. Zock, D. Kromhout, and P. C. H. Hollman, “Effects of the pure flavonoids epicatechin and quercitin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial,” *American Journal of Clinical Nutrition*, vol. 101, no. 5, pp. 914–921, 2015.

[18] S. D. S. Banjarnahor and N. Artanti, “Antioxidant properties of flavonoids,” *Medical Journal of Indonesia*, vol. 23, no. 4, pp. 239–244, 2014.

[19] X. Shi, D. Liu, J. Zhang et al., “Extraction and purification of total flavonoids from pine needles of Cedrus deodara contribute to anti-tumor in vitro,” *BMC Complementary and Alternative Medicine*, vol. 16, article no. 245, 2016.

[20] L.-G. Chen, L.-Y. Hung, K.-W. Tsai et al., “Wogonin, a bioactive flavonoid in herbal tea, inhibits inflammatory cyclooxygenase-2 gene expression in human lung epithelial cancer cells,” *Molecular Nutrition and Food Research*, vol. 52, no. 11, pp. 1349–1357, 2008.

[21] S. Chen, L. Zhang, G. Yan et al., “Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker in patients with ovarian cancer: a meta-analysis,” *BioMed Research International*, vol. 2017, pp. 1–7, 2017.

[22] F. Chen, R. Wu, Z. Zhu et al., “Wogonin protects rat dorsal root ganglion neurons against tunicamycin-induced ER stress through the PERK-eIF2α-ATF4 signaling pathway,” *Journal of Molecular Neuroscience*, vol. 55, no. 4, pp. 995–1005, 2015.

[23] D. Wozniak, A. Drys, and A. Matkowski, “Antiradical and antioxidant activity of flavones from *Scutellaria baicalensis* radix,” *Natural Product Research*, vol. 29, no. 16, pp. 1567–1570, 2015.

[24] D.-H. Lee, C. Kim, L. Zhang, and Y. J. Lee, “Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells,” *Biochemical Pharmacology*, vol. 75, no. 10, pp. 2020–2033, 2008.

[25] D.-H. Lee, T. H. Lee, C. H. Jung, and Y.-H. Kim, “Wogonin induces apoptosis by activating the AMPK and p53 signaling pathways in human glioblastoma cells,” *Cellular Signalling*, vol. 24, no. 11, pp. 2216–2225, 2012.

[26] L. Yang, H.-W. Zhang, R. Hu et al., “Wogonin induces GI phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical carcinoma HeLa cells,” *Biochemistry and Cell Biology*, vol. 87, no. 6, pp. 933–942, 2009.

[27] N. Lu, Y. Gao, Y. Ling et al., “Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEGFR2,” *Life Sciences*, vol. 82, no. 17-18, pp. 956–963, 2008.

[28] X. Song, Y. Zhou, M. Zhou et al., “Wogonin influences vascular permeability via Wnt/β-catenin pathway,” *Molecular Carcinogenesis*, vol. 54, no. 7, pp. 501–512, 2015.

[29] J. Q. Yu, H. B. Liu, D. Z. Tian, Y. W. Liu, J. C. Lei, and G. L. Zou, “Changes in mitochondrial membrane potential and reactive oxygen species during wogonin-induced cell death in human hepatoma cells,” *Hepatology Research*, vol. 37, no. 1, pp. 68–76, 2007.

[30] J. Feng, S. Zhang, K. Wu et al., “Combined effects of suberylanilide hydroxamic acid and cisplatin on radiation sensitivity and cancer cell invasion in non-small cell lung cancer,” *Molecular Cancer Therapeutics*, vol. 15, no. 5, pp. 842–853, 2016.

[31] G. Liu, G. Guan, and J. Fang, “*Macleaya cordata* extract decreased diarrhea score and enhanced intestinal barrier function in growing piglets,” *BioMed Research International*, vol. 2016, Article ID 1069585, 7 pages, 2016.

[32] G. Liu, S. Chen, J. Zhong, K. Teng, and Y. Yin, “Crosstalk between tryptophan metabolism and cardiovascular disease, mechanisms, and therapeutic implications,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 1602074, 5 pages, 2017.

[33] W. L. W. Hsiao and L. Liu, “The role of traditional Chinese herbal medicines in cancer therapy—from TCM theory to mechanistic insights,” *Planta Medica*, vol. 76, no. 11, pp. 1118–1131, 2010.

[34] C. Hu, M. Xu, R. Qin, W. Chen, and X. Xu, “Wogonin induces apoptosis and endoplasmic reticulum stress in HL-60 leukemia cells through inhibition of the PI3K-AKT signaling pathway,” *Oncology Reports*, vol. 33, no. 6, pp. 3146–3154, 2015.

[35] W. Wang, Q. Guo, Q. You et al., “Involvement of bax/bcl-2 in wogonin-induced apoptosis of human hepatoma cell line
SMMC-7721,” Anti-Cancer Drugs, vol. 17, no. 7, pp. 797–805, 2006.

[36] K. F. Huang, G. D. Zhang, Y. Q. Huang, and Y. Diao, "Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway," International Immunopharmacology, vol. 12, no. 2, pp. 334–341, 2012.

[37] S. H. Erdman, H. D. Wu, L. J. Hixon, D. J. Ahnen, and E. W. Gerner, “Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats,” Molecular Carcinogenesis, vol. 19, no. 2, pp. 137–144, 1997.

[38] F. Kruiswijk, C. F. Labuschagne, and K. H. Vousden, “p53 in survival, death and metabolic health: a lifeguard with a licence to kill,” Nature Reviews Molecular Cell Biology, vol. 16, no. 7, pp. 393–405, 2015.

[39] V. Kirkin, S. Joos, and M. Zörnig, “The role of Bcl-2 family members in tumorigenesis,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1644, no. 2-3, pp. 229–249, 2004.

[40] M. K. Manion and D. M. Hockenbery, “Targeting BCL-2-related proteins in cancer therapy,” Cancer Biology & Therapy, vol. 2, supplement 1, no. 4, pp. S105–S114, 2003.

[41] F. Acconcia, P. Totta, S. Ogawa et al., "Survival versus apoptotic 17β-estradiol effect: role of ERα and ERβ activated non-genomic signaling," Journal of Cellular Physiology, vol. 203, no. 1, pp. 193–201, 2005.

[42] L. Mauro, M. Pellegrino, F. Giordano et al., “Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells,” FASEB Journal, vol. 29, no. 5, pp. 2150–2160, 2015.

[43] E. Burandt, M. Grünert, A. Lebeau et al., “Cyclin D1 gene amplification is highly homogeneous in breast cancer,” Breast Cancer, vol. 23, no. 1, pp. 111–119, 2016.

[44] X. Li, X. Gong, J. Chen, J. Zhang, J. Sun, and M. Guo, “MiR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2,” Biochemical and Biophysical Research Communications, vol. 460, no. 3, pp. 670–677, 2015.

[45] Y.-F. Tao, N.-N. Wang, L.-X. Xu et al., “Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells,” Cancer Cell International, vol. 17, no. 1, article no. 35, 2017.